- This event has passed.
BioForum – Journey from Australia to Global Pharmaceutical Markets: Leveraging European Engagement
June 18 @ 4:00 pm - 6:30 pm AEST
Event Navigation
For a more in-depth look at this topic, take a deep-dive into our Biopharma Masterclass Program – Bridging Discovery to Clinical: A Roadmap for European Market Success. The program includes this BioForum along with a full-day workshop and one-on-one advisory session.
About the BioForum
Join international experts Serum Life Science Europe GmbH for an exploration of the intricacies of Europe’s dynamic clinical and regulatory ecosystem.
Gain valuable insights into business strategy and regulation, and see how they are applied for various products, conditions and clinical trials.
Be informed about:
- European regulatory strategy: Unlock the advantages of Europe’s pharmaceutical development
- Global development strategies: From initial research to market launch, learn the essential steps
- Special focus areas:
- Indication: Oncology, rare diseases, paediatric trials and advanced therapy medicinal products
- Expanding into Europe: Navigate multinational trials and bridging studies with confidence
- Real-world applications: Explore impactful case studies.
What to expect:
- The latest updates from industry experts
- Dynamic panel Q&A session
- In-person networking opportunities with peers.
Who should attend?
- Biopharma professionals and industry service providers, ranging from academia and start-ups, through to SMEs and corporates
- Biotech and pharma companies transitioning from discovery to clinical stages
- Early-stage companies (late pre-clinical / clinical stage) with ambitions to develop products for the local or global market
- Biopharma professionals seeking to improve knowledge and foster connections.
BioForum details:
Date: Tuesday 18 June 2024
Time (AEST):
3:45 pm: Guest arrival and registration
4:00 pm: Presentations
5:00 pm: Panel and Q&A
5:30 pm: Networking
6:30 pm: Close
Format: Hybrid – In person and online
Venue: ACMI, Swinburne Studio, Federation Square, Melbourne VIC 3000
Host: Karen Parr, CEO, BioMelbourne Network
Facilitator: Dr Merve Kilinc, Associate Director Business Development, Serum Life Science Europe GmbH
Speakers:
Dr Leander Grode, Managing Director, Serum Life Science Europe GmbH
Dr Fabio Pisano, Chief Development Officer
Dr Marcus May, Medical Director and Qualified Person Responsible for Pharmacovigilance, Serum Life Science Europe GmbH
Panellist: Greg Plunkett, CEO, Accelagen Pty Ltd
BioForum registration
The BioForum is a stand-alone event as well as Part A of the Masterclass Program. Masterclass participants are not required to register separately to attend.
Registration (BioForum only):
In-person: Members $95; Non Members $195
Online: Members $25; Non Members $45
Unsure if your organisation is a member? Check our member directory.
Cancellation policy (BioForum only):
In person registration:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
Online registration:
Full refund given up to 3 days prior to the event
No refunds within 3 days of the event
Kindly sponsored by the State Government of Victoria
In collaboration with Serum Life Science Europe GmbH
and support from Accelagen.
Dr Leander Grode, Managing Director, Serum Life Science Europe GmbH
Leander is the Managing Director at Serum Life Science Europe GmbH since 2019. He has been at the company since 2013, where he was Chief Scientific Officer and Director Business Development (2008).
He is an expert in regulatory affairs, patent strategy and immunology.
Previously, Leander was the coordinator of the vaccine development group at the Max-Planck Institute in the Department of Immunology from 2001 to 2003.
Leander graduated in 1997 with a degree in biology at the Max-Planck Institute of Biophysics in Frankfurt/Main and later completed a PhD from the Max-Planck Institute of Infection Biology. Leander’s doctoral research focused on vaccine development against tuberculosis based on live carriers, including Salmonella or Mycobacterium bovis BCG.
He is an expert in regulatory affairs, patent strategy and immunology.
Previously, Leander was the coordinator of the vaccine development group at the Max-Planck Institute in the Department of Immunology from 2001 to 2003.
Leander graduated in 1997 with a degree in biology at the Max-Planck Institute of Biophysics in Frankfurt/Main and later completed a PhD from the Max-Planck Institute of Infection Biology. Leander’s doctoral research focused on vaccine development against tuberculosis based on live carriers, including Salmonella or Mycobacterium bovis BCG.
Dr Merve Kilinc, Associate Director Business Development, Serum Life Science Europe GmbH
Merve is Associate Director Business Development at Serum Life Science Europe GmbH. With over five years of experience in project management and two years in business development, she focuses on fostering partnerships to support product development initiatives, and steering these projects.
Merve earned Bachelor's and Master's degrees in Molecular Biology and Genetics from Bogazici University, Turkey, and later completed her PhD in Genetics at the University of Cologne. Her doctoral research centered on understanding cellular signaling pathways and their effects on gene expression in health and disease states.
Her core competencies lie in translational and clinical development of pharmaceutical candidates, regulatory interactions, GxP compliance and proficient project management.
Merve earned Bachelor's and Master's degrees in Molecular Biology and Genetics from Bogazici University, Turkey, and later completed her PhD in Genetics at the University of Cologne. Her doctoral research centered on understanding cellular signaling pathways and their effects on gene expression in health and disease states.
Her core competencies lie in translational and clinical development of pharmaceutical candidates, regulatory interactions, GxP compliance and proficient project management.
Dr Marcus May, Medical Director and QPPV, Serum Life Science Europe GmbH
Marcus is Medical Director and QPPV (Qualified Person Responsible for Pharmacovigilance) at Serum Life Science Europe GmbH. He is a Medical Doctor with almost 20 years of experience in clinical practice, academia and the pharmaceutical industry. He is a Board Accredited Clinical Pharmacologist and has a Master’s degree in Health Business Administration.
Marcus is an expert in medicine and GCP-regulations, methods in clinical research, pharmacovigilance and healthcare economics.
He has extensive experience conducting over 70 clinical trials in various indications with small molecules, advanced therapy medicinal products or vaccines, and setting up clinical development strategies for investigational medicinal products.
Previously, Marcus was a senior investigator and head of clinical operations for an academic site management organisation and later as Medical Expert, Medical Director and QPPV at SLS Europe, where he gained extensive expertise in ICH regulations, quality management, regulatory affairs and post-marketing pharmacovigilance.
After Marcus received his license to practice medicine in 2007, he worked in two hospitals as a resident physician in internal medicine. In 2011, he completed his doctoral thesis.
Marcus is an expert in medicine and GCP-regulations, methods in clinical research, pharmacovigilance and healthcare economics.
He has extensive experience conducting over 70 clinical trials in various indications with small molecules, advanced therapy medicinal products or vaccines, and setting up clinical development strategies for investigational medicinal products.
Previously, Marcus was a senior investigator and head of clinical operations for an academic site management organisation and later as Medical Expert, Medical Director and QPPV at SLS Europe, where he gained extensive expertise in ICH regulations, quality management, regulatory affairs and post-marketing pharmacovigilance.
After Marcus received his license to practice medicine in 2007, he worked in two hospitals as a resident physician in internal medicine. In 2011, he completed his doctoral thesis.
Dr Fabio Pisano, Chief Development Officer, Serum Life Science Europe GmbH
Fabio is Chief Development Officer at Serum Life Science Europe GmbH and is responsible for all aspects of project management and consulting services. He joined SLS Europe as a Project Manager and Quality Assurance Manager, and later specialised in product development and regulatory consulting.
Key Knowledge Areas:
• Regulatory consulting
• Good Manufacturing Practice
• Portfolio development.
Fabio studied pharmaceutical biotechnologies at the University of Bologna and performed his doctoral studies at the Helmholtz Centre for Infection Research in Braunschweig. Afterwards, he worked as a postdoctoral researcher in the field of immunology and infectious diseases, with a special focus on virulence strategies of the enteric pathogens Yersinia and Salmonella. After training as a Project Management Associate, he worked as a Scientific Officer at the German Centre for Infection Research (DZIF).
Key Knowledge Areas:
• Regulatory consulting
• Good Manufacturing Practice
• Portfolio development.
Fabio studied pharmaceutical biotechnologies at the University of Bologna and performed his doctoral studies at the Helmholtz Centre for Infection Research in Braunschweig. Afterwards, he worked as a postdoctoral researcher in the field of immunology and infectious diseases, with a special focus on virulence strategies of the enteric pathogens Yersinia and Salmonella. After training as a Project Management Associate, he worked as a Scientific Officer at the German Centre for Infection Research (DZIF).
Greg Plunkett, CEO, Accelagen
Greg is the CEO and Managing Director of Accelagen, founding the company in 2010. He is an innovative, values-driven and forward-thinking senior regulatory affairs professional. Greg has over 20 years of experience in product development, quality and management. Driving excellence, innovation and ingenuity, he is a passionate advocate for healthcare accessibility and bringing the best technologies and innovation to the masses.
